Dec 2 |
, NCT05705167 | A Multicentre, Open Label, Randomised, Controlled, Basket, Pragmatic, Phase II, Clinical and Translational Study to Determine the Efficacy and Safety of Plitidepsin Versus Control in Immunocompromised Adult Patients With Symptomatic COVID-19 Requiring Hospital Care |
| 36% higher mortality (p=1). RCT 37 hospitalized immunocompromised patients, showing no significant benefit with plitidepsin treatment. | ||
Aug 26 |
et al., Clinical Infectious Diseases, doi:10.1093/cid/ciae227 | A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19 |
| 1% lower mortality (p=1). RCT with 205 hospitalized moderate COVID-19 patients showing a trend towards faster time to sustained withdrawal of oxygen supplementation with plitidepsin treatment (1.5 mg/day or 2.5 mg/day for 3 days) compared to standard of care. The .. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.